Search Medical Condition
Please enter condition
Please choose location from dropdown

Five Dock, Australia Clinical Trials

A listing of Five Dock, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (667) clinical trials

A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)

This is an adaptive, open-label, dose-finding study of PRN1008 in up to 40 patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/L on two counts no sooner than 7 days apart in the 15 days before treatment begins. The ...

Phase

1.38 miles

Learn More »

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

Study Design: Subjects will be randomly assigned in a 1:1 ratio to receive either cobomarsen or vorinostat. A total of 126 subjects (63 per arm) will be enrolled. Cobomarsen will be administered in the clinic by 2-hr intravenous infusion on Days 1, 3, 5 and 8, and weekly thereafter. Vorinostat ...

Phase

1.38 miles

Learn More »

Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Na ve Subjects Who Require Red Blood Cell Transfusions

Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes, an umbrella term used to describe disorders relating to the ineffective production of red blood cells, white blood cells, and/or platelets. Ranging in severity from mild (asymptomatic) to severe, anemia can result in ...

Phase

1.38 miles

Learn More »

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 240 study centers, globally. The investigational drug (sparsentan) is a dual-acting angiotensin receptor blocker and endothelin receptor antagonist. The ...

Phase

1.38 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.

Phase

1.38 miles

Learn More »

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

This is a randomized, multicenter, double-blind, parallel-group, active-control study. Approximately 280 patients aged 18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan. The purpose of the study is to evaluate ...

Phase

1.38 miles

Learn More »

Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)

Background: Cardiac Resynchronization Therapy (CRT) is an established treatment in heart failure (HF) patients with ventricular dyssynchrony who remain in sinus rhythm. Available clinical data has shown inferior outcomes of CRT in HF patients with co-existent atrial fibrillation (AF), who comprise up to 27% of HF patients, and are over-represented ...

Phase N/A

1.57 miles

Learn More »

ANCHOR (Aneurysm Treatment Using the Heli-FX EndoAnchor System Global Registry)

The objective of the ANCHOR registry is to expand the clinical knowledge based on the use of the Heli-FX EndoAnchor System. This registry will include "real world" use over a broad spectrum of geographies, by a wide variety of practicing clinicians, and with a minimal degree of subject selection criteria.

Phase N/A

1.57 miles

Learn More »

Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

Globally, over 2 million people receive dialysis for end-stage renal disease (ESRD) and 650,000 new patients start dialysis each year. Furthermore, the number of patients receiving dialysis is increasing as access to dialysis in the developing world improves and the prevalence of diabetes and vascular disease rises. Despite technical advances ...

Phase

1.57 miles

Learn More »

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

This is an open-label, randomized active control study of BGB-3111 plus obinutuzumab versus obinutuzumab alone in subjects with relapsed or refractory follicular lymphoma. Randomization is 2:1 and subjects will be stratified by the number of prior lines of therapy (2 - 3 vs > 3) and rituximab-refractory status. The study ...

Phase

1.57 miles

Learn More »